Shawn R. Johnson
Overview
Shawn Johnson is a partner and co-chair of Crowell & Moring's Antitrust and Competition Group and is located in the firm's Washington, D.C. office.
Career & Education
- Boston College, B.A., economics and political science
- Vanderbilt University Law School, J.D., Managing Editor, Vanderbilt Law Review
- District of Columbia
- Virginia (Inactive)
Shawn's Insights
Client Alert | 3 min read | 10.17.25
California Enacts New Requirements and Restrictions for Health Care Transactions
California recently enacted two laws instituting new restrictions and requirements for health care transactions. On October 6, Governor Newsom signed SB 351, which codifies elements of the state’s corporate practice of medicine doctrine and strengthens restrictions against private equity, hedge fund, and other private investor control of health care organizations and operations. On October 11, Newsom signed AB 1415, which expands the scope of parties and relevant transactions that require pre-transaction notice to the state’s Office of Health Care Affordability (OHCA). Both laws are intended to provide the State of California greater oversight of transactions involving health care entities, and raise additional hurdles for parties seeking to acquire or sell health care operations in the state,[1] consistent with a broader trend across the country. The key points of each of the California laws are summarized below:
Firm News | 8 min read | 08.21.25
Client Alert | 1 min read | 07.21.25
Firm News | 11 min read | 06.05.25
Representative Matters
Representative Merger Experience
- Representing United Technologies in connection with its $135 billion merger with The Raytheon Company, which The Deal named its 2020 "Deal of the Year," its $30 billion acquisition of Rockwell Collins, and its $16.5 billion acquisition of Goodrich.
- Representing Sikorsky Aircraft Company in connection with its $9 billion sale to Lockheed Martin.
- Representing Humana in connection with its proposed $37 billion merger with Aetna, as well as its acquisitions of Arcadian Health, Curo Health Services, and the Kindred at Home division of Kindred Healthcare.
- Representing Coventry Health Care in connection with its $5.7 billion sale to Aetna.
- Representing Pratt & Whitney in connection with the $550 million sale of its Rocketdyne business unit to GenCorp.
- Representing Alcoa in connection with its $2.85 billion acquisition of Firth Rixson and its $1.5 billion acquisition of RTI International Metals.
- Representing AT&T (and previously SBC) in connection with numerous transactions, including its acquisitions of AT&T Wireless, AT&T Corp., BellSouth, DirecTV, and Time Warner.
- Representing DuPont in connection with its $6.3 billion acquisition of Danisco and the $4.9 billion divestiture of its automotive paints business to the Carlyle Group.
- Representing Clean Harbors in connection with its acquisitions of both Thermo Fluids and the industrial cleaning services division of Veolia North America.
- Representing Rio Tinto in connection with the $761 million sale of the Jacobs Ranch coal mine to Arch Coal, as well as the divestiture of its Alaskan gold and silver mining operations.
- Representing Bank of America Merrill Lynch, Citigroup, Commerzbank, Goldman Sachs, HSBC, and J.P. Morgan in connection with the formation of FXSpotStream LLC.
- Representing Bank of America, Citigroup, Credit Suisse, Deutsche Bank, Goldman Sachs, JPMorgan Chase, Merrill Lynch and UBS in the formation of ICE US Trust LLC.
- Representing Citadel Securities, GETCO, Goldman Sachs, Morgan Stanley and UBS in their purchase of a significant equity interest in NYSE Liffe U.S.
- Several confidential transactions involving U.S. and foreign intelligence and defense contractors.
Representative Litigation Experience
- Representing a major metals manufacturer in connection with an investigation by the Department of Justice and various international competition authorities into alleged pricing fixing; closed without prosecution.
- Representing a major multinational corporation in connection with an investigation by the Federal Trade Commission into potential monopolization and abuse of standard setting concerns; closed without prosecution.
- Representing a major multinational corporation in connection with an investigation by the Federal Trade Commission into potential monopolization and exclusive dealing concerns; closed without prosecution.
- Representing an agricultural cooperative in connection with an investigation by the Department of Justice into alleged price fixing; closed without prosecution.
- Representing several clients in connection with internal antitrust investigations.
Shawn's Insights
Client Alert | 3 min read | 10.17.25
California Enacts New Requirements and Restrictions for Health Care Transactions
California recently enacted two laws instituting new restrictions and requirements for health care transactions. On October 6, Governor Newsom signed SB 351, which codifies elements of the state’s corporate practice of medicine doctrine and strengthens restrictions against private equity, hedge fund, and other private investor control of health care organizations and operations. On October 11, Newsom signed AB 1415, which expands the scope of parties and relevant transactions that require pre-transaction notice to the state’s Office of Health Care Affordability (OHCA). Both laws are intended to provide the State of California greater oversight of transactions involving health care entities, and raise additional hurdles for parties seeking to acquire or sell health care operations in the state,[1] consistent with a broader trend across the country. The key points of each of the California laws are summarized below:
Firm News | 8 min read | 08.21.25
Client Alert | 1 min read | 07.21.25
Firm News | 11 min read | 06.05.25
Insights
Antitrust in the Digital Age
|02.26.20
Crowell & Moring's Regulatory Forecast 2020
Antitrust — Healthcare Industry in the Spotlight
|01.19.16
Crowell & Moring's Regulatory Forecast 2016
Regulatory Forecast 2016: What Corporate Counsel Need to Know for the Coming Year
|01.19.16
a Crowell & Moring LLP publication
Mergers & Acquisitions: Understanding the Antitrust Issues, Fourth Edition
|10.01.15
ABA Section of Antitrust Law
Regulatory Forecast 2015: What Corporate Counsel Need to Know for the Coming Year
|01.31.15
a Crowell & Moring LLP publication
Antitrust Compliance: Perspectives and Resources for Corporate Counselors, Second Edition
|10.21.10
ABA Section of Antitrust Law
Back In The Cross Hairs: Consortium Deals Can Raise Competition Concerns
|09.02.09
The Deal Magazine
Shawn's Insights
Client Alert | 3 min read | 10.17.25
California Enacts New Requirements and Restrictions for Health Care Transactions
California recently enacted two laws instituting new restrictions and requirements for health care transactions. On October 6, Governor Newsom signed SB 351, which codifies elements of the state’s corporate practice of medicine doctrine and strengthens restrictions against private equity, hedge fund, and other private investor control of health care organizations and operations. On October 11, Newsom signed AB 1415, which expands the scope of parties and relevant transactions that require pre-transaction notice to the state’s Office of Health Care Affordability (OHCA). Both laws are intended to provide the State of California greater oversight of transactions involving health care entities, and raise additional hurdles for parties seeking to acquire or sell health care operations in the state,[1] consistent with a broader trend across the country. The key points of each of the California laws are summarized below:
Firm News | 8 min read | 08.21.25
Client Alert | 1 min read | 07.21.25
Firm News | 11 min read | 06.05.25
